ABOS - NASDAQ
Acumen Pharmaceuticals, Inc.
$2.29
-0.65%Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
At a Glance
Live SnapshotAcumen Pharmaceuticals, Inc. Management Team
Mr. Daniel J. O'Connell M.B.A.
Chief Executive Officer & Director
Compensation
$1,047,590
Mr. Matt Zuga
Chief Financial Officer & Chief Business Officer
Compensation
$703,157
Mr. Derek M. Meisner Esq., J.D.
Chief Legal Officer & Corporate Secretary
Compensation
$752,945
Mr. Russell Barton M.S.
Chief Operating Officer
Compensation
$223,680
Dr. Caleb E. Finch Ph.D.
Co-Founder
Dr. Grant A. Krafft Ph.D.
Co-Founder
Compensation
$42,000
Dr. William L. Klein Ph.D.
Co-Founder
Dr. James Doherty Ph.D.
President & Chief Development Officer
Compensation
$730,785
Ms. Alex Braun M.B.A.
Vice President & Head of Investor Relations
Ms. Kelly Carranza
Vice President, Finance & Accounting and Corporate Controller
Acumen Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $116K and sold $220K worth of ABOS shares, resulting in $105K of net selling activity.
3 Months
0
0.00
2.1K
6.81K
-7K
-$7K
3-6 Months
0
0.00
98.0K
213.60K
-214K
-$214K
6-9 Months
50.0K
95.00K
0
0.00
+95K
+$95K
9-12 Months
19.5K
20.86K
0
0.00
+21K
+$21K
Top Buyers
Golumbeski George
Director
$95K
Stalfort John A Iii
Director
$21K
Top Sellers
Meisner Derek M
Officer: Chief Legal Officer & Corp Sec
$118K
Zuga Matt
Officer: Cfo & Chief Business Officer
$46K
Oconnell Daniel Joseph
Director, Officer: Chief Executive Officer
$22K
Doherty James J.
Officer: President And Cdo
$15K
Barton Russell
Officer: Chief Operating Officer
$12K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $105K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
ABOS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | June 04, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 22, 2024 | June 04, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 27, 2023 | June 06, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 15, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.